Pure Global AI
NCT06324188Not yet recruiting

Early Atrial Fibrillation Ablation for Stroke Prevention in Patients With High Comorbidity Burden (EASThigh-AFNET 11)

Atrial Fibrillation NetworkClinicalTrials.govother
Verified
Study focus
Disease/Condition
Atrial Fibrillation
Drug/Device/Intervention
Early atrial fibrillation ablation
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Atrial Fibrillation Network
Location
Multiple Locations,Multiple Locations,Multiple Locations,Multiple Locations,Multiple Locations, Australia,Canada,Germany,Netherlands,United Kingdom
Timeline & enrollment
Phase
N/A
Start date
Jun 01, 2024
End date
May 01, 2030
Enrollment
2312 participants
Primary outcome

Composite of cardiovascular complications related to AF,The primary safety outcome is a composite of all-cause death and serious complications of AF therapy.

Summary

EASThigh-AFNET 11 is an international, prospective, randomized, open, blinded endpoint
 assessment, multicenter trial (Treatment Strategy trial).
 
 The objective of EASThigh-AFNET 11 is to investigate whether early atrial fibrillation
 ablation in patients with atrial fibrillation (AF) and a high comorbidity burden
 (CHA2DS2-VASc ≥4) reduces cardiovascular events (stroke, cardiovascular death, or heart
 failure events) compared to usual care.

ICD-10 classifications
Chronic atrial fibrillationPersistent atrial fibrillationParoxysmal atrial fibrillationAtrial fibrillation and flutterAtrial fibrillation and atrial flutter, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06324188
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06324188 through Pure Global AI's free database. This phase not specified trial is sponsored by Atrial Fibrillation Network and is currently Not yet recruiting. The study focuses on Atrial Fibrillation. Target enrollment is 2312 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.